Pilot Trial of Colchicine for Graft Failure in CABG

Launched by RUIJIN HOSPITAL · Jan 30, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring whether a medication called colchicine can help improve the success of heart bypass grafts (CABG) after surgery. Colchicine is an oral medicine that some researchers believe might reduce the chances of graft failure, which is when the grafts do not work as well as they should. The study is in its early stages, and the researchers want to see if using colchicine for one year can make a difference in how well the grafts perform. They will compare patients taking colchicine to those who do not receive it to find out if it really helps.

To be eligible for this trial, participants must be at least 18 years old and have recently undergone a successful isolated CABG surgery. They will need to give their consent to join the study and will be followed closely for a year with regular check-ins at one, six, and twelve months after their surgery. Participants will take a daily dose of colchicine and undergo special imaging tests to assess their grafts. This trial is important for understanding whether colchicine can be a useful treatment for improving graft outcomes in heart surgery patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age≥18 years old，
• • Any sex，
• • Signed informed consent，
• • Within 3 days after a successful isolated CABG
• Exclusion Criteria:
• • Allergy,
• • Hematopoietic dysfunction,
• • Moderate to severe hepatic dysfunction,
• • Moderate to severe renal dysfunction.